Ali Mehdi, MD, MEd, is a board-certified nephrologist at Cleveland Clinic, where he also serves as assistant professor of medicine at the Lerner College of Medicine at Case Western Reserve University.

Clinicians treating IgA nephropathy (IgAN) face a disease that can behave in strikingly different ways from one patient to the next, from a rapid decline in kidney function to a slower course marked by hematuria and proteinuria. Matching that variability to the right treatment remains one of the field's harder problems.

Why IgA Nephropathy Risk Stratification Still Falls Short

"IgA nephropathy is a heterogeneous disease," Ali Mehdi, MD, MEd, a board-certified nephrologist at Cleveland Clinic and assistant professor of medicine at the Lerner College of Medicine at Case Western Reserve University, said in an interview with HCPLive. "We have patients who present with a fast, progressive kidney disease where they lose kidney function pretty rapidly over a few years, and we have patients who have hematuria and proteinuria, that it's an indolent progression towards the need of renal replacement therapy down the line."

Current Risk Tools Rely on Damage Already Done

Clinicians currently lean on a mix of clinical and pathologic markers to gauge a patient's trajectory. "We do have some ways to monitor these patients and risk stratify based on clinical parameters like proteinuria, like estimated GFR, and then pathologic parameters that we get from a kidney biopsy," Mehdi said, pointing to tools such as the Oxford Classification (1). Those measures help estimate a patient's risk of progressing to end-stage kidney disease, but Mehdi was direct about their limits. "That is not a perfect way to do it, and we are learning more from clinical trials how to better do it and better identify which patient would benefit more from what disease," he said.

Part of what's driving renewed attention to risk stratification, Mehdi said, is a broader shift in how the field understands IgAN's natural history. Where the disease was once considered relatively benign, a substantial share of patients, even those with seemingly indolent presentations, are now known to eventually require renal replacement therapy, sometimes decades after diagnosis in patients who are first affected in their 30s or 40s. That recognition has already been incorporated into the updated Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (2).

Phenotyping, Not Just Biomarkers, Is the Next Target

Mehdi said the next step is moving past biomarkers that reflect damage already done, such as estimated GFR slope and proteinuria, toward phenotyping that reflects the biology driving a given patient's disease. "I'd like to be able to better phenotype my patients based on disease parameters that would tell me that this patient is high risk and would benefit from treatment X or Y, or would not benefit from treatment X or Y," he said. He expects that shift within the next 5 to 10 years, with the potential to change how clinicians select treatment for individual patients.

Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. 

Kidney Disease: Improving Global Outcomes (KDIGO) IgAN/IgAV Work Group. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). 

Videos

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Strategic Alliance Partnership

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

• A JAAD commentary cautions against cross-trial comparisons of radiographic outcomes among IL-23 inhibitors in psoriatic arthritis due to differences in trial design and patient selection.
• Baseline structural damage explained most of the variance (R² = 0.95; r = 0.97) in placebo-arm radiographic progression across 6 contemporary PsA trials.
• APEX enrolled a biologic-naive, erosion-enriched population, yielding higher placebo progression (1.35 points) than DISCOVER-2 (0.95), FUTURE 5 (0.50), SPIRIT-P1 (0.49), KEEPsAKE-1 (0.32), and BE OPTIMAL (0.31).
• The authors advise weighing radiographic data alongside skin efficacy, joint control, safety, and how closely trial populations match the patient being treated.

Journal of the American Academy of Dermatology 

argues radiographic outcomes across interleukin-23 inhibitor trials in 

, including guselkumab's (Tremfya) phase 3b APEX trial, reflect trial design and patient selection rather than comparative efficacy.¹

The letter, authored by dermatologists David Oberlin, MD, of Forefront Dermatology, and Jesse Veenstra, MD, PhD, of Henry Ford Health and Michigan State University, responds to renewed interest in APEX's radiographic findings for guselkumab. Cross-trial comparisons among interleukin (IL)-23 inhibitors have been complicated by a lack of comparably enriched trial populations, since APEX required baseline erosive disease in a biologic-naive cohort while other IL-23 inhibitor studies did not.² The authors caution against inferring comparative superiority or inferiority from radiographic endpoints collected under different design conditions.

"The most informative trial is not necessarily the one with the largest effect, but the one whose participants most closely resemble the patient being treated," wrote David Oberlin, MD, and Jesse Veenstra, MD, PhD.¹

Guselkumab and Cross-Trial Radiographic Data in Psoriatic Arthritis

APEX enrolled 1020 biologic-naive patients with active PsA and required baseline erosive disease, producing a population enriched for structural risk. Through week 24, the mean placebo-arm baseline radiographic score was 26.8, and the placebo arm progressed by a mean of 1.35 points. Guselkumab-treated arms progressed by only 0.55 points every 4 weeks (Q4W) and 0.54 points every 8 weeks (Q8W).¹

DISCOVER-2 also enrolled a biologic-naive, inflammation-enriched population of 741 patients but did not require baseline erosions. Mean placebo-arm baseline score was 23.8, with placebo progression of 0.95 points versus 0.29 points with guselkumab Q4W and 0.52 points with Q8W, though the Q8W comparison did not reach statistical significance.²

KEEPsAKE-1 enrolled a broader, less structurally damaged population of 964 patients treated with risankizumab (Skyrizi). Mean placebo baseline score was only 13.5, with placebo progression of 0.32 points and a treatment-arm change of 0.23 points, a difference the authors note did not reach statistical significance.³

Baseline Joint Damage and Comparator Biologic Classes in PsA

Across the 6 trials analyzed, baseline structural damage correlated strongly with placebo-arm radiographic progression (R² = 0.95; r = 0.97), the authors reported. Study population and trial duration, rather than treatment class, appeared to drive much of the observed variance in placebo progression.¹

BE OPTIMAL, a bimekizumab (Bimzelx) trial, enrolled 852 patients with a mean baseline score of 12.3 and minimal placebo progression of 0.31 points at week 16.¹ FUTURE 5, a secukinumab (Cosentyx) trial (n = 996), and SPIRIT-P1, an ixekizumab (Taltz) trial (n = 417), showed similarly low placebo progression, 0.50 and 0.49 points respectively, despite biologic-naive enrollment criteria in each.¹

The commentary presents no new safety data, focusing instead on structural-outcome interpretation. The authors note radiographic signals are harder to isolate statistically when placebo-arm progression is inherently low, regardless of an agent's anti-inflammatory activity. They advise clinicians to weigh radiographic evidence alongside skin clearance, joint control, safety, and how closely a trial's population matches the patient under consideration.

The authors observed a similar pattern among IL-17 inhibitors and older tumor necrosis factor (TNF) inhibitor trials, where low absolute placebo-arm progression limited visibility of treatment effects despite established radiographic benefit for these classes.¹ They conclude study design and baseline population, rather than comparative potency alone, should guide interpretation of radiographic data when counseling patients on biologic selection for PsA in dermatology practice.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Oberlin D, Veenstra J. Interpreting radiographic outcomes across IL-23 inhibitor trials in psoriatic arthritis: the role of trial design. J Am Acad Dermatol. Published online 2026. 

Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active psoriatic arthritis: results through week 24 of the phase 3b randomized, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025;84:1983-1994.

Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis: a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395:1126-1136.

Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomized, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81:225-231.

Articles

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Trial Design Drives Radiographic Outcomes Across IL-23 Inhibitors in PsA

For patients with chronic kidney disease (CKD), timing matters. Many of the same risk factors that increase a person's likelihood of incarceration, including poverty, limited health care access, and untreated chronic disease, also raise the risk of developing CKD, according to Laura J. Maursetter, MD, Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health.

Why CKD Treatment Should Start Earlier, Last Longer for Incarcerated Persons

Why Early Detection Matters More in High-Risk Populations

CKD and incarceration risk factors substantially overlap

Custody status can affect medication access and administration oversight

Reentry brings acute barriers: meds, appointments, housing, transport

Early screening is cost- and outcome-effective, per Maursetter

"We have so much room to be able to impact an outcome of someone's life if we start earlier," Maursetter told 

, noting that identifying kidney disease at an earlier stage makes a meaningfully bigger difference than catching it later in its course.

She acknowledged that primary care physicians already carry heavy caseloads, but argued that screening high-risk populations earlier is not just clinically sound, but financially justified.

"Being able to look for these things earlier, especially in these high-risk populations, is cost-effective, and that's been shown, as well as outcome-effective," she said.

She also cited recent momentum in the field, including new kidney medications introduced within the past 2 years that have meaningfully extended patient longevity.

Maursetter cautioned that clinicians who see justice-involved patients only briefly, either during a single visit or after release, often have little visibility into what patients experienced while incarcerated.

Custody structures vary by facility and can shift a patient's access to medications depending on their housing classification. And it's often unclear, she said, whether patients are self-administering medications or receiving them under supervision, a distinction that matters when doses are missed or prescriptions lapse without being refilled.

What Happens to Care After Incarceration Ends

Patients leaving incarceration often face immediate and compounding obstacles, Maursetter said: reestablishing interrupted medications, securing timely follow-up appointments, and doing so while navigating unstable housing and unreliable transportation.

"I think of the correctional facility as being a time where you're serving your time for the things that you were convicted for, but then afterward, there's so much that follows those patients," she said.

Maursetter called on clinicians and health systems to build flexibility into how they accommodate returning patients — including making room in scheduling for people who could not plan visits in advance. "How can we kind of build a structure to allow for some of those nuances that may not be the same in all of the rest of our patients?" she said.

Editor’s Note: Maursetter reports no relevant disclosures. 

Maursetter LJ. Nephrology care for incarcerated people: a call to action. 

. Published online July 28, 2026. doi:10.1038/s41581-026-01108-7

Kumar M, Stauss M, Taylor P, Maursetter L, Woywodt A. 10 tips for providing kidney care to persons in prison. 

. 2025;18(5):sfaf090. doi:10.1093/ckj/sfaf090

American Society of Nephrology. People Living with Kidney Failure in Detention Facilities: Frequently Asked Questions (FAQs). Published March 2026. Accessed August 25, 2026. 

https://epc.asn-online.org/wp-content/uploads/2026/02/Kidney-Failure-in-Detention-Facilities-FAQ.pdf

Laura J. Maursetter, MD, discusses why early kidney disease screening and continuity of care are especially critical for justice-involved patients.


Chronic Kidney Disease

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Casey Halpern, MD, is the chief of the section of stereotactic and functional neurosurgery at Penn Medicine and the founder and chairman of SynchNeuro, Inc.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Non-invasive glucose monitoring is entering a new phase, with an EEG-based wearable positioned to sense blood sugar through brain rhythms rather than interstitial fluid. Early data from the developer suggest the approach may anticipate glucose changes ahead of standard continuous glucose monitors (CGMs), a claim rooted in the physiology of glucose transit from bloodstream to tissue.

On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, professor of neurosurgery and chief of stereotactic and functional neurosurgery at the University of Pennsylvania, about SynchNeuro, the company he cofounded to develop the device.

Diabetes Dialogue: Non-Invasive EEG Sensor Aims to Track Glucose in Real Time

Halpern's group originally identified the underlying signal while using deep brain stimulation electrodes to study 

, finding that certain brain rhythms tracked blood glucose in real time regardless of electrode location. Because the signal is diffuse rather than localized, the team determined it could be captured non-invasively via scalp EEG, most reliably over the temporal lobe, an area accessible with a small sensor worn behind the ear. Device positioning has proven forgiving, with built-in signal-quality feedback guiding users to adjust placement as needed.

Accuracy data remain preliminary, drawn from EEG recordings paired with CGM readings in several dozen users over up to two weeks of continuous wear. Comparing readings synchronized to standard CGM timing, the sensor's mean absolute relative difference runs around 10% to 11%, approaching the accuracy range typically reported for interstitial fluid-based devices. Notably, Halpern reported that accuracy improves when comparing the sensor's output from 20 minutes earlier against subsequent CGM readings, suggesting the EEG signal reflects blood glucose upstream of the diffusion delay inherent to interstitial fluid sensing.

The company is enrolling additional users toward an algorithm-training cohort in the hundreds, which Halpern said internal power calculations suggest should be sufficient before pursuing regulatory clearance. Plans include an initial focus on type 2 diabetes and prediabetes, with a potential wellness-category launch preceding a full US Food and Drug Administration clinical-claims pathway. Beyond glucose, the platform is being explored for ketone monitoring, sleep apnea, and stroke risk prediction, applications that would each require separate regulatory work.

Collectively, the findings position EEG-based glucose sensing as a potential complement or alternative to interstitial fluid CGMs, particularly for patients seeking a non-invasive, intermittently wearable option, though larger validation cohorts and regulatory review will determine whether the anticipatory accuracy signal holds up at scale.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Halpern reports being a consultant for Insightec and employment with SynchNeuro.

Kinsey N. SynchNeuro Has a Working Prototype, a New Study Launching, and a Forecast for Your Blood Sugar | Health Moonshot Update. 

. May 27, 2026. Accessed August 26, 2026. 

https://media.startuphealth.com/p/synchneuro-has-a-working-prototype-a-new-study-launching-and-a-forecast-for-your-blood-sugar-health-

Podcasts

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, to discuss SynchNeuro's investigational, non-invasive EEG-based glucose monitor.

Type 2 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Jennifer A. Dantzer, MD, MHS, assistant professor of pediatrics, Johns Hopkins University School of Medicine.

A long-term follow-up of the IMPACT trial found 80% (32/40) of children treated with 

 starting at 1 to 3 years of age were still eating peanut 8 to 11 years later. Despite this finding, lead author Jennifer A. Dantzer, MD, MHS, assistant professor of pediatrics at Johns Hopkins University School of Medicine, said the field still lacks a fully powered study to answer whether these patients are in durable remission.¹

The IMPACT-PLuS study enrolled 78 of the original 146 IMPACT participants and paired questionnaire data on ongoing consumption and reactions with serologic follow-up in 58 patients.¹ Dantzer said no coordinated effort currently exists to build the kind of long-term dataset the field needs.

"I think what would be very helpful would be just more years of data for who's still eating it, how's it going, who's having reactions," Dantzer said.

Peanut OIT Follow-Up Study Highlights Gaps in Allergy Remission Research

She added that confirming true remission would require pausing consumption entirely and rechallenging patients months later. However, this approach can be difficult to counsel families through given the risk of reaction on reintroduction.

IMPACT-PLuS Long-Term Consumption and Immunologic Findings

Among the 40 patients who received pnOIT in IMPACT with no subsequent intervention, 35% (14/40) reported peanut reactions since the original trial, and 5 required epinephrine.¹ All 15 patients who had achieved remission in IMPACT were still eating peanut at follow-up, with 60% (9/15) consuming at least 1000 mg per serving.¹ Compared with the placebo arm, pnOIT-treated patients maintained significantly lower peanut and Ara h 2 IgE and higher IgG4 levels years after the original trial ended (

 <.001 for peanut IgE), suggesting sustained immune modulation rather than a transient treatment effect.¹

Predictive Biomarkers and Remission Testing Remain Unanswered

What did the IMPACT-PLuS follow-up study show?


Among children treated with peanut OIT starting at 1 to 3 years of age, 80% were still eating peanut 8 to 11 years later, with sustained changes in peanut-specific IgE and IgG4 levels.

What research gap remains in early-life peanut OIT?


There is no coordinated long-term follow-up effort, and confirming true immunologic remission would require pausing peanut consumption and performing a formal rechallenge, which researchers have not yet organized at scale.

Dantzer said the most pressing unresolved questions are identifying which patients respond best to pnOIT and whether a laboratory marker could predict success before treatment begins. She also raised a distinct long-term question: whether a marker could eventually distinguish patients who could safely space out dosing from those who have naturally outgrown their allergy altogether and no longer need to track intake at all.

Dantzer emphasized that clinicians should continue referring food-allergic children to allergists or seeing them regularly if already practicing allergy, given the expanding menu of approved and investigational treatment options. She said families and clinicians should decide together which option, if any, fits a given child.

Early-Life Peanut OIT's Decade-Long Benefit, With Jennifer Dantzer, MD

Peanut OIT Long-Term Reaction Risk, Remission, and Biomarkers

Dantzer JA, Virkud YV, Cox AL, et al. Early life peanut oral immunotherapy associated with long-term ingestion and immunologic changes. 

Dantzer J. Early-Life Peanut OIT’s Decade-Long Benefit, With Jennifer Dantzer, MD. HCPLive. Published August 24, 2026. Accessed August. 25, 2026. 

https://www.hcplive.com/view/early-life-peanut-oit-decade-benefit-jennifer-dantzer-md

Dantzer J. IMPACT-PLuS Data Show Low but Real Reaction Risk with Peanut OIT. HCPLive. August 25, 2026. 

https://www.hcplive.com/view/peanut-oit-long-term-reaction-risk-remission-biomarkers

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

In this episode, co-hosts Isaacs and Bellini are joined by Eden Miller, DO, and Davida Kruger, NP, to discuss the FDA's recent clearance of the FreeStyle Libre Duo ketone monitor.

Type 1 Diabetes

Diabetes Dialogue: FreeStyle Libre Duo Cleared for Ketone Monitoring

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

FDA News

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and building patient trust and adherence.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: Advice on Diagnosing Psoriasis in Diverse Skin Tones

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

Saakshi Khattri, MD, discusses mental health screening gaps in psoriasis and a new Th17/type 2 immune signature study pointing toward personalized care.

Q&A: Mental Health and Precision-Medicine Gaps in Psoriasis Care Today

Jonathan Downar, MD, PhD, FRCPC, associate professor of the Department of Psychiatry at the University of Toronto and co-founder of Ampa.

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

More TMS Pulses Track with Better Depression Outcomes, With Jonathan Downar, MD

Saakshi Khattri, MD, discusses oral TYK2 inhibitor and IL-23 antagonist data alongside weight-loss combination therapy reshaping psoriasis and PsA care.

Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes

Wojciech Zareba, MD, PhD, is a professor of medicine and cardiology at the University of Rochester Medical Center.

Wojciech Zareba, MD, PhD, discusses his recent study comparing the efficacy of the KardiaMobile 6-Lead to Holter ambulatory ECGs.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Latest News

Why IgA Nephropathy Risk Stratification Still Falls Short

Trial Design Drives Radiographic Outcomes Across IL-23 Inhibitors in PsA

Why CKD Treatment Should Start Earlier, Last Longer for Incarcerated Persons

Diabetes Dialogue: Non-Invasive EEG Sensor Aims to Track Glucose in Real Time

Peanut OIT Follow-Up Study Highlights Gaps in Allergy Remission Research